Julien Torgue, Ph.D.
Julien Torgue, Ph.D., graduated from Florida Institute of Technology with a B.S. in Biochemistry, 2003, and a Ph.D. in molecular Biology, 2007.
His career started as a Project Manager at a Contract Manufacturing Organization, Goodwin Biotechnology, where he oversaw the development, production and regulatory filings of antibodies for clinical trials. In 2010, he transitioned to a Senior Scientists and Project Manager at another CMO prior to accepting the position of Scientific Director for the recently formed biotech, AREVA Med. He was tasked with filing an IND for the first in human use of ²¹²Pb, which was submitted to the FDA in December 2010, managing the Phase 1 clinical trial and multiple other scientific partnerships with academic and industrial partners. As AREVA Med expanded, he took an increasing role in the strategic development of the company and continues to oversee AREVA Med research taking place in the US and France, as well as a leading scientific role in the co-development alliance signed between Roche and AREVA Med. Dr. Torgue was elected member of the Macrocyclics board of directors in July 2015.